|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4409450A
(en)
|
1982-07-29 |
1983-10-11 |
Amp Incorporated |
Double pole membrane switch having preferred sequence closing feature
|
|
IL71275A0
(en)
|
1983-03-21 |
1984-06-29 |
Sparamedica Ag |
Human interleukin-2-and its preparation
|
|
FR2573436B1
(fr)
|
1984-11-20 |
1989-02-17 |
Pasteur Institut |
Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
WO1991018088A1
(en)
|
1990-05-23 |
1991-11-28 |
The United States Of America, Represented By The Secretary, United States Department Of Commerce |
Adeno-associated virus (aav)-based eucaryotic vectors
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
JPH07505887A
(ja)
|
1992-04-17 |
1995-06-29 |
アボツト・ラボラトリーズ |
タキソール誘導体
|
|
AU680459B2
(en)
|
1992-12-03 |
1997-07-31 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
ATE157882T1
(de)
|
1993-03-23 |
1997-09-15 |
Smithkline Beecham Biolog |
3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
|
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
BR9405507A
(pt)
|
1993-07-13 |
1999-05-25 |
Rhone Poulenc Rorer Sa |
Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
ATE509102T1
(de)
|
1994-07-15 |
2011-05-15 |
Univ Iowa Res Found |
Immunomodulatorische oligonukleotide
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US5912264A
(en)
|
1997-03-03 |
1999-06-15 |
Bristol-Myers Squibb Company |
6-halo-or nitrate-substituted paclitaxels
|
|
US6319913B1
(en)
|
1997-11-10 |
2001-11-20 |
Cellegy Pharmaceuticals, Inc. |
Penetration enhancing and irritation reducing systems
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
AT406376B
(de)
|
1998-01-16 |
2000-04-25 |
Immuno Ag |
Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
|
|
JPH11268865A
(ja)
|
1998-03-20 |
1999-10-05 |
Omron Corp |
用紙仕分け装置及び方法
|
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
US6198323B1
(en)
|
1999-01-28 |
2001-03-06 |
Lucent Technologies Inc. |
Flip-flop having gated inverter feedback structure with embedded preset/clear logic
|
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
US20030180352A1
(en)
|
1999-11-23 |
2003-09-25 |
Patel Mahesh V. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US6967023B1
(en)
|
2000-01-10 |
2005-11-22 |
Foamix, Ltd. |
Pharmaceutical and cosmetic carrier or composition for topical application
|
|
CO5280224A1
(es)
|
2000-02-02 |
2003-05-30 |
Univ Florida State Res Found |
Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
|
|
CN1291012C
(zh)
|
2000-03-14 |
2006-12-20 |
巴法里安诺迪克有限公司 |
修饰的安卡拉牛痘病毒(mva)的变株
|
|
EP1272630A2
(en)
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
|
EP1276501B9
(en)
|
2000-04-25 |
2007-01-24 |
Immunex Corporation |
Method for treatment of tumors using photodynamic therapy
|
|
US7179483B2
(en)
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
AU2001265187A1
(en)
|
2000-05-30 |
2001-12-11 |
Baylor College Of Medicine |
Chimeric viral vectors for gene therapy
|
|
US8512718B2
(en)
|
2000-07-03 |
2013-08-20 |
Foamix Ltd. |
Pharmaceutical composition for topical application
|
|
CN1252260C
(zh)
|
2000-07-21 |
2006-04-19 |
上海三维生物技术有限公司 |
肿瘤特异性启动子
|
|
AU1152402A
(en)
|
2000-10-04 |
2002-04-15 |
Univ Pennsylvania |
Highly expressible genes
|
|
EP1213025A1
(de)
|
2000-12-06 |
2002-06-12 |
Laboratoires Serobiologiques(Societe Anonyme) |
Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa
|
|
AU2002221565A1
(en)
|
2000-12-08 |
2002-06-18 |
Novo-Nordisk A/S |
Trefoil factor 2 (tff2) peptides with moiety attached to asn15
|
|
ATE437221T1
(de)
|
2001-05-14 |
2009-08-15 |
Gbp Ip Llc |
Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
|
|
JP2003009883A
(ja)
|
2001-07-05 |
2003-01-14 |
Mitsubishi Pharma Corp |
マスト細胞の細胞死誘発剤
|
|
AU2002350409A1
(en)
|
2001-10-26 |
2003-05-06 |
Uffe Holmskov |
Surfactant protein-d and atherosclerosis
|
|
US7368122B1
(en)
|
2002-03-08 |
2008-05-06 |
Dow Pharmaceutical Sciences |
Skin cream
|
|
EP2269619A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Methods and compositions concerning poxviruses and cancer
|
|
DE60330407D1
(de)
|
2002-08-23 |
2010-01-14 |
Sloan Kettering Inst Cancer |
Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
|
|
GB0226251D0
(en)
|
2002-11-11 |
2002-12-18 |
San Raffaele Centro Fond |
Acetylated protein
|
|
US20040143026A1
(en)
|
2002-12-31 |
2004-07-22 |
Shah Kishore R. |
Bioadhesive hydrophilic composition for treatment of mammalian skin
|
|
NZ570709A
(en)
|
2003-06-13 |
2010-04-30 |
Univ Pennsylvania |
Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
|
|
EP1644492B1
(en)
|
2003-06-18 |
2009-01-07 |
Genelux Corporation |
Modified recombinant vaccinia viruses, uses thereof
|
|
CA2882022A1
(en)
|
2003-09-11 |
2005-03-24 |
Walter Newman |
Monoclonal antibodies against hmgb1
|
|
EP1528101A1
(en)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
US7638132B2
(en)
|
2003-12-05 |
2009-12-29 |
National University Corporation Hokkaido University |
Highly safe smallpox vaccine virus and vaccinia virus vector
|
|
DE102004030044A1
(de)
|
2004-06-22 |
2006-01-12 |
Birken Gmbh |
Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
|
|
CA2592627C
(en)
*
|
2005-01-20 |
2014-02-25 |
Isconova Ab |
Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
|
|
US20100094560A1
(en)
|
2006-08-15 |
2010-04-15 |
Prometheus Laboratories Inc. |
Methods for diagnosing irritable bowel syndrome
|
|
DK2062023T4
(en)
|
2006-08-25 |
2017-02-20 |
The Government Of The Us Secretary Dept Of Health And Human Services |
INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS
|
|
WO2008023077A2
(en)
|
2006-08-25 |
2008-02-28 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin |
Compositions and methods for modulating an immune response
|
|
EP2426142A3
(en)
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
GB0702695D0
(en)
|
2007-02-12 |
2007-03-21 |
Ark Therapeutics Ltd |
Production of vectors
|
|
US8003363B2
(en)
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
EP2176288B1
(en)
|
2007-07-10 |
2015-11-04 |
Apogenix GmbH |
Tnf superfamily collectin fusion proteins
|
|
US20090136917A1
(en)
|
2007-10-25 |
2009-05-28 |
Szalay Aladar A |
Systems and methods for viral therapy
|
|
KR20140130512A
(ko)
|
2008-03-06 |
2014-11-10 |
할로자임, 아이엔씨 |
가용성 히알루로니다아제의 대규모 제조
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
SI2119726T2
(en)
|
2008-05-14 |
2018-03-30 |
Immatics Biotechnologies Gmbh |
New and powerful Class II MHC peptides derived from survivin and neurocane
|
|
JP2012500229A
(ja)
|
2008-08-21 |
2012-01-05 |
オタワ ホスピタル リサーチ インスティチュート |
遺伝子操作された相乗的腫瘍溶解性ウイルス共生
|
|
CN101381742A
(zh)
|
2008-10-23 |
2009-03-11 |
浙江理工大学 |
晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
|
|
EP2184297A1
(en)
|
2008-11-07 |
2010-05-12 |
Hla-G Technologies |
HLA-G polypeptides and pharmaceutical uses thereof
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
CA2709292A1
(en)
|
2009-07-10 |
2011-01-10 |
The Governors Of The University Of Alberta |
Oncolytic viruses and methods for treating neoplastic disorders
|
|
WO2012036215A1
(ja)
|
2010-09-17 |
2012-03-22 |
Taniguchi Tadatsugu |
Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
KR101942237B1
(ko)
|
2011-01-04 |
2019-01-25 |
신라젠(주) |
종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
|
|
EP2527459A1
(en)
|
2011-05-02 |
2012-11-28 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Blood-based gene detection of non-small cell lung cancer
|
|
EP2739293B1
(en)
|
2011-08-05 |
2020-06-10 |
SillaJen Biotherapeutics, Inc. |
Methods and compositions for production of vaccina virus
|
|
FI20115914A7
(fi)
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10806697B2
(en)
|
2012-12-21 |
2020-10-20 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
|
EP2877572B1
(en)
|
2012-07-24 |
2018-11-28 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
|
EP2900810B1
(en)
|
2012-09-28 |
2019-02-20 |
ProBioGen AG |
Novel mva virus and uses thereof
|
|
US9180091B2
(en)
|
2012-12-21 |
2015-11-10 |
Therapeuticsmd, Inc. |
Soluble estradiol capsule for vaginal insertion
|
|
KR20140122603A
(ko)
|
2013-04-10 |
2014-10-20 |
신라젠(주) |
세포외 피막성 백시니아 바이러스의 생성과 관련된 단백질을 코딩하는 폴리뉴클레오티드로 형질전환된 숙주세포
|
|
ES3011466T3
(en)
|
2013-04-18 |
2025-04-07 |
Tilt Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
|
WO2015007536A2
(en)
|
2013-07-18 |
2015-01-22 |
Vib Vzw |
Fusokines involving cytokines with strongly reduced receptor binding affinities
|
|
DK3036329T3
(da)
|
2013-08-22 |
2021-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Immunonkolytiske terapier
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
US20150259420A1
(en)
*
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
MA39818A
(fr)
|
2014-03-30 |
2017-02-08 |
Benevir Biopharm Inc |
Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
|
|
US20160060314A1
(en)
|
2014-08-27 |
2016-03-03 |
Daewoong Jo |
Development of a Protein-Based Biotherapeutic Agent That Penetrates Cell-Membrane and Induces Anti-Tumor Effect in Solid Tumors - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Tumor Compositions Comprising the Same
|
|
HRP20190881T1
(hr)
*
|
2014-08-28 |
2019-07-12 |
Halozyme, Inc. |
Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
|
|
ES2753391T3
(es)
*
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
|
WO2016061826A1
(zh)
|
2014-10-24 |
2016-04-28 |
华为技术有限公司 |
模式复用解复用器和交换节点
|
|
EP4122492A1
(en)
|
2015-02-25 |
2023-01-25 |
Memorial Sloan Kettering Cancer Center |
Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
|
|
ES2861450T3
(es)
|
2015-07-20 |
2021-10-06 |
Virttu Biologics Ltd |
Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer
|
|
HK1255192A1
(zh)
*
|
2015-09-08 |
2019-08-09 |
Sillajen, Inc. |
表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
JP7025339B2
(ja)
|
2016-02-25 |
2022-02-24 |
メモリアル スローン ケタリング キャンサー センター |
癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
CN110022867A
(zh)
*
|
2016-09-21 |
2019-07-16 |
斯蒂芬·H·索恩 |
高迁移率族蛋白box i突变体
|
|
US20200046784A1
(en)
|
2016-09-30 |
2020-02-13 |
University Health Network |
Recombinant oncolytic viruses for cancer therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
US11185586B2
(en)
|
2016-11-22 |
2021-11-30 |
Alloplex Biotherapeutics, Inc. |
Allogeneic tumor cell vaccine
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
AU2018223211B2
(en)
|
2017-02-21 |
2025-02-27 |
Adelaide university |
T cells expressing chemokine receptors for treating cancer
|
|
TWI672677B
(zh)
|
2017-03-31 |
2019-09-21 |
鈺立微電子股份有限公司 |
用以融合多深度圖的深度圖產生裝置
|
|
WO2019055860A1
(en)
|
2017-09-15 |
2019-03-21 |
The Texas A&M University System |
METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER
|
|
EP3973973A1
(en)
|
2017-10-31 |
2022-03-30 |
KaliVir Immunotherapeutics, Inc. |
Platform oncolytic vector for systemic delivery
|
|
US11786569B2
(en)
|
2018-01-26 |
2023-10-17 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
|
|
BR112020022181A2
(pt)
|
2018-05-02 |
2021-02-09 |
Tonix Pharma Holdings Limited |
vírus vaccinia quimérico sintético
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
EP3876951A1
(en)
|
2018-11-06 |
2021-09-15 |
Calidi Biotherapeutics, Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
|
US11529402B2
(en)
|
2019-01-14 |
2022-12-20 |
Ignite Immunotherapy, Inc. |
Recombinant vaccinia virus and methods of use thereof
|
|
JP2022520220A
(ja)
|
2019-02-14 |
2022-03-29 |
イグナイト イミュノセラピー インク |
組換えワクシニアウイルスおよびその使用方法
|
|
JP7732977B2
(ja)
|
2019-09-20 |
2025-09-02 |
トランスジーン |
Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ
|
|
CA3163805A1
(en)
|
2019-12-12 |
2021-06-17 |
Ignite Immunotherapy, Inc. |
Variant oncolytic vaccinia virus and methods of use thereof
|
|
WO2021140435A1
(en)
|
2020-01-09 |
2021-07-15 |
Pfizer Inc. |
Recombinant vaccinia virus
|
|
MX2023000734A
(es)
|
2020-07-14 |
2023-02-13 |
Pfizer |
Virus vaccinia recombinante.
|
|
CN112668865A
(zh)
|
2020-12-23 |
2021-04-16 |
贵阳市城市轨道交通集团有限公司 |
一种城市地铁风险动态分析方法
|